1. Biotech IPO bonanza: Legend Biotech, Forma Therapeutics, Repare — COVID-19 could slow progress in reducing cancer death, NCI warns — ASCO 2020 news from Merck, AstraZeneca, Pfizer, more — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Lilly

Discussion in 'Dermira' started by anonymous, Feb 21, 2020 at 7:45 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Great, we are officially big pharma.
     

  2. anonymous

    anonymous Guest

    Until you are not. Get ready for cuts.
     
  3. anonymous

    anonymous Guest

    We are coming for you Taltz reps. You have the best product in the class and consistently under perform, expect to interview for your job. Stay tuned...
     
  4. anonymous

    anonymous Guest

    Lilly will take this 6 month selling process to look to get rid of underperforming reps. Lilly went with non-derm reps, and are paying the price. Taltz has seriously underperformed, and Lilly knows that they need to change things up. 10% - 15% of Lilly sales force will be on PIPs soon.